Patents by Inventor Sven Andrecht

Sven Andrecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10793592
    Abstract: The present invention relates to the purification of target molecules like recombinant and/or biotherapeutic proteins. Activated carbon can be used to remove leachables and/or extractables resulting from disposable equipment employed in the process.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Romas Skudas, Klaus Adrian, Bianca Edlemann, Sven Andrecht, Wilson Moya
  • Publication number: 20170313741
    Abstract: The present invention relates to the purification of target molecules like recombinant and/or biotherapeutic proteins. Activated carbon can be used to remove leachables and/or extractables resulting from disposable equipment employed in the process.
    Type: Application
    Filed: October 20, 2015
    Publication date: November 2, 2017
    Applicant: Merck Patent GmbH
    Inventors: Romas SKUDAS, Klaus ADRIAN, Bianca EDLEMANN, Sven ANDRECHT, Wilson MOYA
  • Patent number: 7407812
    Abstract: The invention relates to a method and a kit for the isolation of phosphorylated peptides from complex mixtures using support materials having chelate ligands based on silica and alkaline elution buffers. In preferred embodiments, the method according to the invention enables the isolation of phosphopeptides from complex sample solutions with a reproducibly high yield and at the same time with high purity and it allows efficient ionisation and detection of the isolated phosphopeptides both by MALDI-TOF and also by ESI mass spectrometry without additional requisite method steps, such as, for example, chromatographic desalination of the sample.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: August 5, 2008
    Assignee: Merck Patent GmbH
    Inventors: Jonas Anders, Achim Schwämmle, Sven Andrecht, Robertus Hendriks, Anette Boerner, Cora Rueter
  • Publication number: 20070227974
    Abstract: The invention relates to a method and a kit for the isolation of phosphorylated peptides from complex mixtures using support materials having chelate ligands based on silica and alkaline elution buffers. In preferred embodiments, the method according to the invention enables the isolation of phosphopeptides from complex sample solutions with a reproducibly high yield and at the same time with high purity and it allows efficient ionisation and detection of the isolated phosphopeptides both by MALDI-TOF and also by ESI mass spectrometry without additional requisite method steps, such as, for example, chromatographic desalination of the sample.
    Type: Application
    Filed: April 21, 2005
    Publication date: October 4, 2007
    Inventors: Jonas Anders, Achim Schwammle, Sven Andrecht, Robertus Hendriks, Anette Boerner, Cora Rueter
  • Patent number: 6846674
    Abstract: The invention relates to genetically modified fibroblast cells which comprise the following properties: (a) a gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor of the signal transduction pathway is modified resulting in a modified AP-1 activity; (b) functionally linked with a promoter, it contains in an expression vector the gene from (a) in a form such that the active subunit is only expressed after induction of the promoter or the subunit encoded by the gene is present in inactive form and a form that can be activated.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: January 25, 2005
    Assignee: Deutsche Krebsforschungszentrum Stiftung des Offentlichen rechts
    Inventors: Peter Angel, Norbert Fusenig, Andrea Kolbus, Marina Schorpp-Kistner, Axel Szabowski, Nicole Maas-Szabowski, Sven Andrecht
  • Publication number: 20030109474
    Abstract: The invention relates to genetically modified fibroblast cells which comprise the following properties: (a) a gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor of the signal transduction pathway is modified resulting in a modified AP-1 activity; (b) functionally linked with a promoter, it contains in an expression vector the gene from (a) in a form such that the active subunit is only expressed after induction of the promoter or the subunit encoded by the gene is present in inactive form and a form that can be activated.
    Type: Application
    Filed: July 15, 2002
    Publication date: June 12, 2003
    Inventors: Peter Angel, Norbert Fusenig, Andrea Kolbus, Marina Schorpp-Kistner, Axel Szabowski, Nicole Maas-Szabowski, Sven Andrecht